Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.30 |
| ▸ | NPC1 | O15118 | 2/20 | 0.30 |
| ▸ | RAB9A | P51151 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5229792 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2MEN1KMT2AMAPTNPC1 | |
| SCHEMBL6139552 | 1.00 | SMN1; SMN2 (0.32) | SMN1; SMN2MEN1KMT2AMAPTNPC1 | |
| SCHEMBL6368684 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL6139474 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL6139469 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL5229563 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2MEN1KMT2AMAPT | |
| SCHEMBL6139952 | 0.81 | — | — | |
| SCHEMBL6139948 | 0.81 | — | — | |
| SCHEMBL5224320 | 0.81 | — | — | |
| SCHEMBL6384767 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-08-25 | — | — | US | disclosed |
| US-6930102-B2 | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | SCHERING AG (DE) | 2005-08-16 | — | — | US | disclosed |
| US-20040014978-A1 | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | SCHERING AG (DE) | 2004-01-22 | — | — | US | disclosed |
| US-6610736-B1 | Antitumor | SCHERING AG (DE) | 2003-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014978-A1 | 16-halogen-epothilone derivatives, process for their production, and their pharmaceutical use | EPOR, CYP2F1, REV1 | SMN1; SMN2 4827/4885MEN1 2578/4885KMT2A 1965/4885 |
| US-20050187270-A1 | 16-Halogen-epothilone derivatives, method for producing them and their pharmaceutical use | ABCB1, UGT2B17, CYP7B1 | SMN1; SMN2 4832/4885MEN1 4391/4885KMT2A 3671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.